HQHaiqing Qian

Haiqing Qian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haiqing Qian has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Lihong Wang

    Department of Reproduction, Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang, Jiangsu, China

    2 shared publications
  • Haiyan Sun

    Department of Anesthesiology, The First Affiliated Hospital of Soochow University, 215006 Suzhou, Jiangsu, China

    1 shared publication
  • Heng Qian

    Translational Medical Innovation Center Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine Zhangjiagang Jiangsu People's Republic of China

    1 shared publication
  • Jiahui Wang

    Nanjing University of Chinese Medicine

    1 shared publication
  • Jiahui Wang

    Department of Reproduction, Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, China

    1 shared publication
  • Lijuan Cui

    Nanjing University of Chinese Medicine

    1 shared publication

Latest Publications

  • Open Access

    From Tradition to Innovation: Acupuncture Therapies Targeting Ferroptosis in Neurological Disorders

    by Haiyan Sun, Haiqing Qian, Heng Qian, Min Qian

    Introduction: Age‐related neurodegenerative diseases (NDDs) and stroke represent significant public health challenges due to their high morbidity, mortality, and associated cognitive decline. Current therapeutic strategies often fall short in addressing the complex underlying pathological mechanisms, underscoring the urgent need for innovative treatment approaches. Ferroptosis, an iron‐dependent form of regulated cell death driven by lipid peroxidation, has emerged as a critical factor contributing to neuronal damage in NDDs and stroke. Methods: To explore how acupuncture‐related therapies may modulate ferroptosis and contribute to neuroprotection, we conducted a comprehensive narrative review. A systematic search was performed in PubMed using targeted keywords including “ferroptosis,” “interventions” (such as acupuncture, electroacupuncture, and moxibustion), and “diseases” (including age‐related neurodegenerative diseases and stroke). The search was restricted to articles published before April 2025 with full‐text availability in English. Results: This review consolidates recent findings on the potential of acupuncture‐related therapies to target ferroptosis in NDDs and stroke. Traditional acupuncture, electroacupuncture (EA), and moxibustion have shown promising neuroprotective effects through multiple mechanisms. Emerging evidence suggests that these interventions can regulate ferroptosis by modulating key molecular pathways involved in iron metabolism, lipid peroxidation, and oxidative stress. These actions are thought to alleviate synaptic dysfunction and slow cognitive decline—processes where ferroptosis plays a central role. Such insights enhance our understanding of how traditional Chinese medicine could influence cognitive outcomes in age‐related NDDs and stroke. Conclusion: Understanding the role of ferroptosis in NDDs and stroke is essential for developing novel therapeutics. Based on current findings, this review proposes future research directions aimed at integrating acupuncture into modern neurotherapeutic frameworks. Combining traditional medicine with contemporary medical approaches offers new opportunities for promoting brain health and improving patient outcomes.


  • Open Access

    Efficacy of Bushen Huatan Decoction combined with Baduanjin in the treatment of polycystic ovary syndrome with insulin resistance (IR-PCOS), kidney deficiency and phlegm dampness: study protocol for a randomized controlled trial

    by Haiqing Qian, Wenting Xu, Lijuan Cui, Rong Wang, Jiahui Wang, Mengyu Tang, Minggang Wei, Lihong Wang

    Background: Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disease in women. Insulin resistance (IR) has emerged as a central contributor to the pathogenesis of this disease. According to traditional Chinese medicine (TCM), kidney deficiency is the main syndrome of PCOS. The deficiency of the kidney cannot vaporize water-dampness, and the retention of water-dampness accumulates into phlegm dampness stagnation, resulting in visceral dysfunction and metabolic disorder. TCM involving syndrome differentiation and treatment is widely used to adjust women’s menstrual cycles. Our patented formula Bushen Huatan Decoction (BSHTD) has been proven to be effective in the clinical treatment of IR-PCOS. Baduanjin also plays an important role in improving metabolic syndrome through lifestyle intervention. This study investigates the clinical efficacy of Bushen Huatan Decoction combined with Baduanjin in IR-PCOS, to form a specific TCM-behaviour intervention plan in the treatment of IR-PCOS. Methods/design: This is a randomized controlled trial involving 190 participants diagnosed with IR-PCOS. All participants will be randomly allocated into 5 groups: group A will receive metformin; group B, BSHTD; group C, Baduanjin; group D, BSHTD combined with metformin; and group E, BSHTD combined with Baduanjin. One course of treatment lasts 3 months, a total of two courses. The primary outcomes are changes in the homeostatic model assessment of insulin resistance (HOMA-IR) and improvements in the oral glucose tolerance test (OGTT) and insulin-releasing test (INS). The secondary outcomes are improvements in the menstrual cycle, ovulation rate, clinical pregnancy rate, basic serum sex hormone levels, free androgen index (FAI), Ferriman-Gallwey scores, body mass index (BMI) and TCM syndrome scores. The related observation indexes will be collected at baseline, during the process of treatment and at the 6-month follow-up. Simultaneously, close monitoring of possible adverse events will be performed throughout the trial process. Discussion: This trial will investigate the efficacy of the comprehensive intervention program of Bushen Huatan Decoction combined with Baduanjin on the adjustment of the menstrual cycle, improvement of insulin resistance and correction of glucose metabolism disorder in IR-PCOS patients. It is expected to form an alternative treatment of TCM-behaviour intervention therapy for IR-PCOS and promote the Chinese fitness Qigong Baduanjin in the application of lifestyle diseases. Trial registration: Chinese Clinical Trial Registry ChiCTR2100043415. Registered on 15 February 2021.


  • Open Access

    Efficacy of Bushen Huatan Decoction Combined with Baduanjin in the Treatment of Polycystic Ovary Syndrome with Insulin Resistance (IR-PCOS), Kidney Deficiency and Phlegm Dampness: Study Protocol for a Randomized Controlled Trial

    by Haiqing Qian, Wenting Xu, Lijuan Cui, Rong Wang, Jiahui Wang, Mengyu Tang, Minggang Wei, Lihong Wang

    Background: Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disease in women. Insulin resistance (IR) has emerged as a central contributor to the pathogenesis of this disease. Traditional Chinese medicine (TCM) involving syndrome differentiation and treatment is widely used to adjust women's menstrual cycles. Our patented formula Bushen Huatan Decoction (BSHTD) has been proven to be effective in the clinical treatment of IR-PCOS. Baduanjin also plays an important role in improving metabolic syndrome through lifestyle intervention. This study investigates the clinical efficacy of Bushen Huatan Decoction combined with Baduanjin in IR-PCOS, to form a specific TCM-behaviour intervention plan in the treatment of IR-PCOS.Methods/design: This is a randomized controlled trial involving 190 participants diagnosed with IR-PCOS. All participants will be randomly allocated into 5 groups: group A will receive metformin; group B, BSHTD; group C, Baduanjin; group D, BSHTD combined with metformin; and group E, BSHTD combined with Baduanjin. One course of treatment lasts three months, a total of two courses. The primary outcomes are changes in the homeostatic model assessment of insulin resistance (HOMA-IR) and improvements in the oral glucose tolerance test (OGTT) and insulin-releasing test (INS). The secondary outcomes are improvements in the menstrual cycle, ovulation rate, clinical pregnancy rate, basic serum sex hormone levels, free androgen index (FAI), Ferriman-Gallwey scores, body mass index (BMI) and TCM syndrome scores. The related observation indexes will be collected at baseline, during the process of treatment and at the 6-months follow-up. Simultaneously, close monitoring of possible adverse events will be performed throughout the trial process.Discussion: This trial will investigate the efficacy of the comprehensive intervention program of Bushen Huatan Decoction combined with Baduanjin on the adjustment of menstrual cycle, improvement of insulin resistance and correction of glucose metabolism disorder in IR-PCOS patients. It is expected to form an alternative treatment of TCM-behavior intervention therapy for IR-PCOS and promote the Chinese fitness Qigong Baduanjin in the application of lifestyle diseases.Trial registration: Chinese Clinical Trial Registry, ChiCTR2100043415. Registered on 15 February,2021.